FDA Grants Breakthrough Therapy Designation to Daraxonrasib Plus Chemotherapy for Untreated Metastatic Pancreatic Cancer
核心洞察
The FDA granted Breakthrough Therapy designation to daraxonrasib combined with gemcitabine and nab-paclitaxel for previously untreated metastatic pancreatic adenocarcinoma (搜索), announced by Revolution Medicines on Sept. 14.
The designation follows the drug's Aug. 26 approval for previously treated metastatic disease, which was based on the phase 3 RASolute 302 trial showing median overall survival of 13.2 versus 6.7 months.
First-line designation rests on the phase 1/2 RMC-GI-102 study of 40 patients, where the combination produced a 58% confirmed response rate with no randomized comparison group.
The FDA has granted Breakthrough Therapy designation to daraxonrasib, the RAS (搜索)-blocking pill sold as Rasonque (搜索), in combination with gemcitabine and nab-paclitaxel for patients with metastatic pancreatic cancer (搜索) who have not yet received treatment. Developer Revolution Medicines announced the designation on Sept. 14, less than three weeks after the drug's first FDA approval.
The designation covers the combination with gemcitabine and nab-paclitaxel, a chemotherapy regimen widely used for this cancer. Using that combination first would move the drug to the start of care instead of reserving it for patients who have already been treated. For newly diagnosed patients and their families, the news is meaningful but limited, because the combination remains investigational.
"This Breakthrough Therapy Designation underscores the significant unmet need among patients with previously untreated metastatic pancreatic adenocarcinoma (搜索)," said Dr. Alan Sandler, the company's chief development officer. Revolution Medicines says this is the third Breakthrough Therapy designation for daraxonrasib.
A Designation, Not an Approval
Breakthrough Therapy designation is intended to speed the development and review of drugs for serious conditions when preliminary clinical evidence suggests a substantial improvement over available therapy on at least one clinically significant endpoint. It brings closer FDA guidance and can support a faster review. It does not mean the agency has found the treatment safe and effective for this use, and it does not guarantee approval.
Daraxonrasib is currently FDA-approved only for the use described in the agency's approval notice for previously treated metastatic disease. The FDA cleared it on Aug. 26 for adults with metastatic pancreatic adenocarcinoma (搜索) who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
That approval rested on the phase 3 RASolute 302 trial, which randomly assigned 500 patients. Median overall survival was 13.2 months with daraxonrasib versus 6.7 months with standard chemotherapy, and median progression-free survival was 7.2 versus 3.6 months. The study was funded by Revolution Medicines.
Early Results From 40 Patients
The first-line designation is based on the phase 1/2 RMC-GI-102 study, an open-label trial without a comparison group. In previously reported results from 40 patients with untreated, RAS (搜索)-mutant metastatic pancreatic cancer (搜索), the combination produced a confirmed response rate of 58%, a measure of meaningful tumor shrinkage, including one complete response.
At a Dec. 1, 2025, data cutoff, median progression-free and overall survival had not yet been reached. Estimated six-month progression-free survival was 84%, and estimated six-month overall survival was 90%. The most common grade 3 or higher treatment-related side effects were anemia, low neutrophil counts, and fatigue.
Those numbers are encouraging but early. Forty patients is a small group; response rates can shift with longer follow-up, and without a randomized control group, it is impossible to say how much of the benefit came from daraxonrasib rather than chemotherapy or from the way patients were selected.
RASolute 303 to Test the First-Line Question
The answer should come from RASolute 303, a global phase 3 trial designed to enroll about 900 people with untreated metastatic pancreatic adenocarcinoma (搜索), regardless of their tumor's RAS (搜索) mutation status. It compares daraxonrasib alone, daraxonrasib plus gemcitabine and nab-paclitaxel, and chemotherapy alone. Its primary goals are progression-free survival and overall survival. Because the 40-patient study enrolled only people whose tumors carried RAS mutations, the larger trial will also show whether any benefit extends to patients without such a mutation.
The mutated protein daraxonrasib targets fuels tumor growth in more than 90% of pancreatic cancers, and the American Cancer Society estimates about 67,000 new U.S. cases this year. That is why moving an effective RAS (搜索) inhibitor earlier in treatment could matter to many patients.
Oncologists have been enthusiastic about the drug's earlier results. Dr. Jeremy Jacox, a gastrointestinal medical oncologist at Yale School of Medicine, described the survival benefit seen in previously treated patients as "arguably the biggest, most important advance in the last 13 to 15 years in pancreatic cancer (搜索)." His comment addressed the single-drug results, not the combination now under study. No timeline for RASolute 303 results accompanied the announcement.
Cost, Access, and Safety Considerations
Revolution Medicines set Rasonque (搜索)'s price at about $39,800 for a one-month supply, according to the Associated Press. Insurance coverage generally follows FDA-approved uses, so first-line use outside a trial may be harder to get covered. Patients can ask about manufacturer assistance programs and their plan's prior authorization rules, and those considering the trial can ask study coordinators which costs are covered and whether travel support is available.
The approved label carries warnings for skin reactions, mouth sores, diarrhea, gastrointestinal perforation, lung inflammation, and harm to a developing fetus. In pancreatic cancer (搜索) trials, skin toxicity occurred in 86% of patients who took the drug, and the label reports 10% as grade 3, a severe level. New cough, shortness of breath, severe abdominal pain, or persistent diarrhea should be reported to the care team right away.
Patients should not stop or change current treatment based on this news. The designation signals FDA interest in a promising approach, but the combination's safety and effectiveness for untreated disease have not been established. Patients interested in first-line access can ask their oncologist about eligibility and check the trial's ClinicalTrials.gov listing for participating sites.